• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs.

作者信息

Scherak O, Popp W, Kolarz G, Wottawa A, Ritschka L, Braun O

机构信息

Institut für Rheumatologie des medizinischen Institutszentrums der Kurstadt Baden, Austria.

出版信息

J Rheumatol. 1993 Jun;20(6):944-9.

PMID:8102405
Abstract

Bronchoalveolar lavage (BAL) and histology of transbronchial forceps biopsy was performed in 59 patients with rheumatoid arthritis (RA) to evaluate the in vivo effects of disease modifying drugs (DMARD). All patients had no clinical pulmonary symptoms and there was no evidence of drug induced alveolitis. Patients were divided into 5 subgroups according to drug treatment: 9 patients taking chloroquine, 15 patients gold, 8 patients penicillamine, 8 patients methotrexate (MTX) and 19 patients not taking DMARD. Duration of DMARD regimen was more than 3 months. No patient was treated with corticosteroids. BAL results revealed an increased percentage of lymphocytes and a diminished proportion of alveolar macrophages in patients treated with gold, penicillamine, MTX and no DMARD. In contrast, patients receiving chloroquine had a normal distribution of lymphocytes and macrophages as seen in a control group of 15 persons. Patients taking MTX showed a normal distribution of T and B lymphocytes and DR positive cells, whereas patients receiving chloroquine, gold, or penicillamine had an elevated proportion of T lymphocytes and DR positive cells and a diminished percentage of B lymphocytes. The latter was also observed in patients not taking DMARD. The percentage of natural killer cells was significantly elevated only in the penicillamine group. Patients receiving gold had higher absolute values of CD3, CD4 and DR positive cells. Abnormal lung histology was associated with an increased percentage of lymphocytes and with higher DR positive cells in BAL. Patients not receiving DMARD had a significantly higher percentage (42.1%) of abnormal histologic features of lung tissue than patients receiving DMARD (17.5%).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs.
J Rheumatol. 1993 Jun;20(6):944-9.
2
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.与甲氨蝶呤单药治疗相比,甲氨蝶呤(MTX)与肌肉注射金制剂或其他改善病情抗风湿药联合用于难治性和破坏性类风湿关节炎的长期治疗。
J Rheumatol. 1998 Aug;25(8):1485-92.
3
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.甲氨蝶呤、羟氯喹和肌肉注射金制剂治疗类风湿关节炎:曲线下相对面积疗效及序贯效应
J Rheumatol. 2002 Aug;29(8):1639-45.
4
Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.类风湿关节炎中的低剂量泼尼松龙:各种改善病情抗风湿药物的不良反应
J Rheumatol. 2008 Jun;35(6):979-85. Epub 2008 Apr 15.
5
Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.美国一家私人诊所中近期发病的类风湿关节炎患者使用当代改善病情抗风湿药(DMARD)的情况:90%的患者以甲氨蝶呤作为基础用药,30%的患者使用新型DMARD。
J Rheumatol. 2002 Dec;29(12):2521-4.
6
Factors influencing length of time taking methotrexate in rheumatoid arthritis.影响类风湿关节炎患者服用甲氨蝶呤时长的因素。
J Rheumatol. 2000 May;27(5):1139-47.
7
Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.疾病改善抗风湿药物令人失望的长期疗效:一项基于实践的研究。
J Rheumatol. 1999 Nov;26(11):2337-43.
8
Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.类风湿关节炎中改善病情抗风湿药的毒性特征
J Rheumatol. 1991 Feb;18(2):188-94.
9
Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.影响改善病情抗风湿药物停用的患者、疾病及治疗相关因素:一项基于人群的类风湿关节炎患者发病队列研究
J Rheumatol. 2006 Feb;33(2):248-55. Epub 2005 Dec 15.
10
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.根据风湿病学家和药剂师的意见,对改善病情抗风湿药与非抗风湿药之间药物相互作用的临床意义进行循证评估。
Clin Ther. 2009 Aug;31(8):1737-46. doi: 10.1016/j.clinthera.2009.08.009.

引用本文的文献

1
A comprehensive summary of disease variants implicated in metal allergy.金属过敏相关疾病变异体的综合总结。
J Toxicol Environ Health B Crit Rev. 2022 Aug 18;25(6):279-341. doi: 10.1080/10937404.2022.2104981. Epub 2022 Aug 16.
2
Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment.甲氨蝶呤相关肺炎与类风湿关节炎-间质性肺疾病:诊断与治疗的当前概念
Front Med (Lausanne). 2019 Oct 23;6:238. doi: 10.3389/fmed.2019.00238. eCollection 2019.
3
Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis.
甲氨蝶呤诱导的肺炎中的支气管肺泡灌洗细胞谱
Thorax. 1997 Apr;52(4):377-9. doi: 10.1136/thx.52.4.377.